Drugs / RTA 901
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02666963 | Jan → Jul 2017 | — | Biogen | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05895552 | Jul 2023 → Nov 2024 | diabetic polyneuropathy | Biogen | Terminated | Missed primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTA 901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05895552 ↗ |
| Route | Oral | “RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose.” NCT02666963 ↗ |